Changes in Perceptions and Confidence of Health Care Professionals across Medical Specialties Regarding Use of SGLT2 and GLP-1 for Cardiorenal Benefit in Type 2 Diabetes

被引：0

作者：

Zytnick, Deena

Woolley, Ryan

Bruns, Michelle

Shay, Christina M.

机构：

来源：

DIABETES | 2021年 / 70卷

关键词：

D O I：

10.2337/db21-143-LB

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

143-LB

引用

页数：3

共 50 条

[41] Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
Goncalves, Edison
Bell, David S. H.
DIABETES THERAPY, 2018, 9 (03) : 919 - 926
[42] SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes
Davila, Esteban
Mccormack, James
ACADEMIC EMERGENCY MEDICINE, 2024, 31 (04) : 408 - 411
[43] PERCEPTIONS OF HEALTH CARE PROFESSIONALS REGARDING HEALTH CARE STANDARDS: THE CASE OF DIABETES TYPE 2 IN THE NETHERLANDS
Raaijmakers, L. G. M.
Bagchus, C.
Martens, M. K.
De, Vries N. K.
Kremers, S. P. J.
INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2012, 19 : S100 - S101
[44] Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
Edison Goncalves
David S. H. Bell
Diabetes Therapy, 2018, 9 : 919 - 926
[45] Evolving physicians' perceptions and practices regarding use of SGLT2 inhibitors for type 2 diabetes during Ramadan fasting
Beshyah, Salem A.
Hafidh, Khadija
Shaikh, Tariq Gul
DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 168
[46] Risk-Benefit of SGLT2 Inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults
Patorno, Elisabetta
Kim, Dae H.
Pawar, Ajinkya
Schneeweiss, Sebastian
Glynn, Robert J.
Munshi, Medha
Bessette, Lily G.
Kim, Seoyoung C.
DIABETES, 2019, 68
[47] Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes
Mei Qiu
Wei Wei
Xu-Bin Wei
Shu-Yan Liu
European Journal of Clinical Pharmacology, 2022, 78 : 695 - 697
[48] Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes?
Pitt, Bertram
Bhatt, Deepak L.
CIRCULATION, 2021, 144 (01) : 4 - 6
[49] Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?
Munir, Kashif M.
Davis, Stephen N.
EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (08) : 773 - 777
[50] Comparisons of Weight Changes between SGLT2 Inhibitors Treatment and GLP-1 Analogs Treatment in Type 2 Diabetes Patients: A Meta-analysis
Cai, Xiaoling
Chen, Yifei
Yang, Wenjia
Zhou, Lingli
Han, Xueyao
Ji, Linong
DIABETES, 2016, 65 : A512 - A512

← 1 2 3 4 5 →